Abstract 1969
Background
In early stage non-small cell lung cancer (NSCLC), the anatomical resection with lymph node dissection is a standard procedure as a curative intent while wedge resection is considered as a passive treatment. However, optimal treatment strategy for elderly ( > = 80 y.o.) patients remains controversial. We attempted to disclose the role of wedge resection without lymph node dissection as a treatment option in octogenarians or older.
Methods
Among 671 patients with clinical stage IA NSCLC with whole tumor size is 2 cm or less and consolidation to tumor ratio is more than 0.5 underwent R0 resection in three institutions between 2010 and 2015, 55 octogenarians or older were investigated about clinicopathological findings and prognosis based on surgical procedures and lymph node dissection status.
Results
The median follow-up time was 35 months. The 3-year overall survival (OS) rate for octogenarians or older was 83.8% (95% confidential interval (CI): 69.7-91.7%). No significant differences for OS were detected among three surgical procedures (3-year OS rate: wedge resection: 88.5% (95%CI: 68.4-96.1%), segmentectomy: 83.3% (95%CI: 27.3-97.5%) , and lobectomy: 78.9% (95%CI: 53.0-91.6%), P = 0.72) or lymph node dissection status (3-year OS rate: ND0: 88.9% (95%CI: 69.4-96.3%) and ND1 or 2: 77.0% (95%CI: 50.8-90.4%), P = 0.95). The multivariable Cox regression analysis revealed that male gender (Hazard ratio (HR): 4.7 (1.1-20.2), P = 0.039) and larger solid tumor size (HR: 5.8 (1.1-29.9), P = 0.035) were independent poor prognostic factors whereas surgical procedure (wedge resection vs. segmentectomy or lobectomy) (HR: 0.50 (0.15-1.7), P = 0.27) was not. In another model, lymph node dissection status (ND0 vs. ND1 or 2) (HR: 0.51 (0.15-1.8), P = 0.28) was not found to be a prognostic factor.
Conclusions
In octogenarians or older with early stage NSCLC, wedge resection without lymph node dissection might be an alternative option to lobectomy or segmentectomy with lymph node dissection.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3690 - PD-L1 expression in resected undifferentiated pleomorphic sarcoma and its clinical implications
Presenter: Kyoungmin Lee
Session: Poster Display session 1
Resources:
Abstract
2013 - PD-L1 expression as a potential therapeutic target and prognostic biomarker in well-differentiated and dedifferentiated liposarcoma.
Presenter: Heejung Chae
Session: Poster Display session 1
Resources:
Abstract
5021 - Soft tissue sarcomas express a distinct mRNA immune profile
Presenter: Viktor Grünwald
Session: Poster Display session 1
Resources:
Abstract
3029 - The molecular landscape of fusion genes in endometrial stromal sarcomas include three nosological entities with different natural history
Presenter: Mehdi Brahmi
Session: Poster Display session 1
Resources:
Abstract
3914 - Clinical validation of a novel assay for the detection of diagnostic alterations in sarcomas
Presenter: Lauren Mc Connell
Session: Poster Display session 1
Resources:
Abstract
1912 - A prospective correlative trial of personalized patient-derived xenograft (PDX) as avatars for drug therapy in patients with metastatic or recurrent soft tissue sarcomas (STS).
Presenter: Kanan Alshammari
Session: Poster Display session 1
Resources:
Abstract
5097 - Fusion of immortalized myoblasts induces genomic instability that drives tumor development and progression.
Presenter: Candice Merle
Session: Poster Display session 1
Resources:
Abstract
1383 - let-7a suppress Ewing sarcoma CSCs' malignant phenotype through forms a positive feedback regulation loop with lin28 via STAT3
Presenter: Xu Jiang
Session: Poster Display session 1
Resources:
Abstract
3386 - Myoepithelial Tumors of Soft Tissues and Extraskeletal Myxoid Chondrosarcomas feature a distinct transcriptional pattern
Presenter: Dominga Racanelli
Session: Poster Display session 1
Resources:
Abstract
1844 - In Vivo Efficacy and Enhanced Tumor Accumulation of Liposomal Vinorelbine (TLC178) in Human Sarcoma Xenograft Mice Model
Presenter: Wan-ni Yu
Session: Poster Display session 1
Resources:
Abstract